In the latest session, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $25.32 down -4.67% from its previous closing price of $26.56. In other words, the price has decreased by -$1.24 from its previous closing price. On the day, 2017337 shares were traded. ARWR stock price reached its highest trading level at $26.75 during the session, while it also had its lowest trading level at $24.75.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
For a deeper understanding of Arrowhead Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 09, 2022, initiated with a Equal-Weight rating and assigned the stock a target price of $41.
On May 11, 2022, Robert W. Baird Upgraded its rating to Outperform which previously was Neutral and also lowered its target price recommendation from $71 to $60.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 when OLUKOTUN ADEOYE Y sold 11,350 shares for $32.65 per share. The transaction valued at 370,578 led to the insider holds 7,867 shares of the business.
GIVEN DOUGLAS B sold 875 shares of ARWR for $28,542 on Feb 27. The Director now owns 13,000 shares after completing the transaction at $32.62 per share. On Jan 09, another insider, Waddill William D., who serves as the Director of the company, sold 3,200 shares for $30.00 each. As a result, the insider received 96,000 and left with 28,950 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.39 while its Price-to-Book (P/B) ratio in mrq is 7.11.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $51.11, while it has fallen to a 52-week low of $25.54. The 50-Day Moving Average of the stock is 33.14, while the 200-Day Moving Average is calculated to be 35.35.
For the past three months, ARWR has traded an average of 1.08M shares per day and 1.56M over the past ten days. A total of 106.04M shares are outstanding, with a floating share count of 103.30M. Insiders hold about 3.40% of the company’s shares, while institutions hold 68.10% stake in the company. Shares short for ARWR as of Jan 30, 2023 were 4.58M with a Short Ratio of 4.62M, compared to 4.74M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.29% and a Short% of Float of 5.12%.
There are 11 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of $0.16 and a low estimate of -$1.09, while EPS last year was $0.41. The consensus estimate for the next quarter is -$0.69, with high estimates of $0.16 and low estimates of -$1.12.
Analysts are recommending an EPS of between $0.66 and -$3.48 for the fiscal current year, implying an average EPS of -$2.21. EPS for the following year is -$2.82, with 10 analysts recommending between $1.38 and -$4.33.
A total of 11 analysts believe the company’s revenue will be $47.54M this quarter.It ranges from a high estimate of $124.7M to a low estimate of $20M. As of the current estimate, Arrowhead Pharmaceuticals Inc.’s year-ago sales were $151.81M, an estimated decrease of -68.70% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $44.51M, an increase of 37.30% over than the figure of -$68.70% in the same quarter last year. There is a high estimate of $124.7M for the next quarter, whereas the lowest estimate is $16.6M.
A total of 11 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $498.8M, while the lowest revenue estimate was $125.9M, resulting in an average revenue estimate of $225.96M. In the same quarter a year ago, actual revenue was $243.23M, down -7.10% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $216.35M in the next fiscal year. The high estimate is $593.2M and the low estimate is $77.2M. The average revenue growth estimate for next year is down -4.30% from the average revenue estimate for this year.